
Marksans Q1 FY27: consolidated PAT jumps 174% YoY to ₹159 Cr as NPM expands to ~19%
margin expansion · acquisition led growth · low base yoy

margin expansion · acquisition led growth · low base yoy

healthcare earnings · hospital capacity · CGHS pricing

fmcg · consumer healthcare · margin compression

dental products · aligners business · margin expansion

pharma cdmo · branded generics · margin expansion

diagnostics · expansion · margin

dental products · margin expansion · labour code impact

animal health · margin expansion · amalgamation

pharmaceuticals · margin compression · acquisition integration

vitamin d3 api · bulk drugs chemicals · margin compression

patent · oncology · intellectual property

pharma · Q1 FY27 · North America growth

pharmaceuticals · turnaround · consolidated pat

pharma · cdmo · margin compression

pharmaceuticals · margin expansion · ebitda growth

lab plasticware · margin compression · consolidated loss

cdmo growth · margin expansion · us market strength

hospitals · healthcare services · margin compression

pharma api · chemical segment · margin expansion

pharma · margin compression · pat decline

pharma r&d · one-off revenue · licensing termination

pharmaceuticals · subsidiary divestment · revenue growth

pharma exports · margin expansion · guidance raise

CDMO · sterile injectables · contract manufacturing

Q1 FY27 · sterile injectables · US generics

CDMO · sterile injectables · USFDA warning letter

SPARC · earnings preview · R&D biotech

ASTRAZEN · pharma · earnings preview

pharma earnings · M&A integration · FDA compliance